Cisplatin-Based Chemotherapy Is a Strong Risk Factor for Thromboembolic Events in Small-Cell Lung Cancer.

Cancer Res Treat · 2015 · PMC4614217 · PMID 25672586

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

marginally significantp=0.08so close (0.05 < p ≤ 0.1)

Cisplatin-based chemotherapy showed association with increased risk of TEE, which was marginally significant (HR, 3.66; 95% confidence interval [CI], 0.87 to 15.43; p=0.08).

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.